Dehydroepiandrosterone in the treatment of systemic lupus erythematosus [9]

Rheumatology

Volumn 39, Issue 8, 2000, Pages 929-930

  Van Vollenhoven, R F ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PLACEBO; PRASTERONE; PREDNISONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; LETTER; MAJOR CLINICAL STUDY; METHODOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

EID: 0033841121     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/39.8.929     Document Type: Letter

References (3)

1. Assessing patients with lupus: Towards a drug responder index
2. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus
3. Results of the GL701 (DHEA) multicenter steroid-sparing SLE study